TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6367665
Drug: Prazosin hydrochloride
Normalized name: Prazosin Hydrochloride
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosin hydrochloride (1 mg orally three times a day)
Study: 27468708
Drug: L-AGE diet
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AGE diet
Study: 24456328
Drug: CERA (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERA (continuous erythropoietin receptor activator)
Study: 17337164
Drug: Duloxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine treatment for 7-14 days
Study: 16255011
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day prednisolone
Study: 23808255
Drug: Parenteral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral feeding
Study: 7493437
Drug: Cholecystokinin-8 infusion
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin-8 infusion
Study: 26089546
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C
Study: 21517955
Drug: Prandial +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial + basal insulin
Study: 19236501
Drug: Neuroaid (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroaid (4 capsules, 3 times daily for 3 months)
Study: 19236501
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules, 3 times daily for 3 months)
Study: 12762431
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment (ET group) with Lansoprazol 30 mg/day for three months
Study: 12762431
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (ST group) with Lansoprazol 30 mg/day for three months
Study: 10175551
Drug: Manually operated
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manually operated metered dose inhaler (MDI)
Study: 3767127
Drug: Albuterol (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (4.0 mg)
Study: 9250445
Drug: Terbutaline (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5.0 mg)
Study: 25091820
Drug: Aspirin (160mg/day)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (160mg/day) plus citalopram (20mg/day)
Study: 18663300
Drug: Fluoridated dentifrice
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated dentifrice (twice per day)
Study: 15363566
Drug: Dutasteride 0.5mg
Normalized name: DUTASTERIDE 0.5MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5mg daily (D/D group)
Study: 15363566
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by Dutasteride 0.5mg daily (P/D group)
Study: 9390608
Drug: Neostigmine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.0 mg and glycopyrrolate 0.4 mg intravenously (Group A)
Study: 9390608
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs to facilitate antagonism of blockade (Group B)
Study: 22381771
Drug: TMZ-RT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ-RT group (60 Gy radiotherapy with concurrent temozolomide treatment)
Study: 22381771
Drug: VM-RT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-RT group (60 Gy radiotherapy with concurrent VM-26 plus Me-CCNU treatments)
Study: 10442154
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement (20,000 IU beta-carotene, 400 IU vitamin E, 500 mg vitamin C, 100 micrograms selenium, 30 mg zinc)
Study: 15467097
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement
Study: 8546287
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (total dose 860 mg, range 540‐1520 mg)
Study: 30922964
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors (DPP-4i)
Study: 30922964
Drug: α-glucosidase inhibitor
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-glucosidase inhibitor (acarbose)
Study: 27856001
Drug: Standard nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutritional therapy (control)
Study: 20025685
Drug: Neoral cyclosporine-based
Normalized name: cyclosporine Oral Capsule [Neoral]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral cyclosporine-based therapy
Study: 11738537
Drug: quetiapine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine 600 mg/day
Study: 17293709
Drug: quetiapine 300
Normalized name: quetiapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine 300 mg/day
Study: 15264726
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg x kg(‐1) pre‐induction bolus followed by intravenous infusion of ketamine 0.5 mg x kg(‐1) x h(‐1) for 72 hours
Study: 15264726
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) as pre‐induction bolus followed by normal saline infusion for 72 hours
Study: 2890398
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml saline (control)
Study: 27229707
Drug: IVB 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB 1.25 mg
Study: 27229707
Drug: IVB 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB 1.25 mg with STA 40 mg
Study: 24111757
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy in critically ill patients
Study: 20855136
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of a fat emulsion (Calogen(®)) 3 times daily, providing 420 kcal
Study: 10858989
Drug: IgE antibody
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE antibody titers to ovalbumin
Study: 1592884
Drug: 30 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms/kg oral GHRP
Study: 1592884
Drug: 100 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms/kg oral GHRP
Study: 1592884
Drug: 300 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms/kg oral GHRP
Study: 6205052
Drug: 4 per
Normalized name: Flex24 Performance
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 per cent chlorhexidine-detergent solution
Study: 6205052
Drug: Routine cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine cord care with 4 per cent chlorhexidine-detergent solution
Study: 2185825
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (GS)
Study: 15346704
Drug: Regrow 120
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regrow 120 mg
Study: 15346704
Drug: Regrow 240
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regrow 240 mg
Study: 11870795
Drug: Pulsed KTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed KTP laser treatment with aqueous gel
Study: 11870795
Drug: Pulsed KTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed KTP laser treatment without aqueous gel
Study: 8861460
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of uncooked cornstarch as part of the 21:00 evening snack
Study: 2177746
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Org 2766 (synthetic analog of ACTH 4‐9)/day for 4 weeks
Study: 6343148
Drug: Oral etretinate
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral etretinate (Tigason)
Study: 25166761
Drug: Twice-daily placebo
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily placebo dentifrice
Study: 25166761
Drug: Twice-daily fluoride
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily fluoride dentifrice
Study: 25166761
Drug: Twice-daily fluoride
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily fluoride dentifrice and once-daily fluoride mouthrinse
Study: 25166761
Drug: Thrice-daily fluoride
Normalized name: potassium nitrate / sodium fluoride Toothpaste [Fluoridex Daily Defense Sensitivity]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily fluoride dentifrice
Study: 11710724
Drug: Colchicine (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1-2 mg/day, adjusted to body weight)
Study: 2958783
Drug: Niaprazine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaprazine (1.5 mg/kg/day)
Study: 26453952
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy (30‐35 kcal/kg/d, 1.0‐1.5 g vegetable protein/kg/d)
Study: 26453952
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no nutritional therapy)
Study: 10530967
Drug: Levodopa-carbidopa (2.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa (2.08 mg/kg of body weight)
Study: 10530967
Drug: Levodopa-carbidopa (0.62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa (0.62 mg/kg of body weight)
Study: 7721374
Drug: Metronidazole (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (22.5 mg/kg/day for 5 days in 3 divided doses)
Study: 21785963
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy with cultural tailoring intervention
Study: 21785963
Drug: Brief medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief medication management (Control)
Study: 25790018
Drug: Seven-day week
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day week therapy (usual care physiotherapy provided seven-days a week)
Study: 25790018
Drug: Circuit class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit class therapy (physiotherapy in group circuit classes in two 90-min sessions, five-days a week)
Study: 23552182
Drug: DHEA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 400 mg
Study: 21347997
Drug: Traditional herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional herbal medicines
Study: 20008182
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies that increase fetal hemoglobin production, improve red blood cell hydration, increase nitric oxide availability, and possess anti-inflammatory effects
Study: 15243932
Drug: V‐TT conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: V‐TT conjugate vaccine (n=22)
Study: 15243932
Drug: Licensed tetanus-diphtheria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed tetanus-diphtheria toxoid vaccine (Td) (n=10)
Study: 1537478
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk containing 10(8)/g Lactobacillus acidophilus and 10(7)/g Bifidobacterium sp
Study: 24347773
Drug: 2 mg/2
Normalized name: risperidone 2 mg/2 mL ORAL SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/2 ml DEZ
Study: 21831266
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (gemcitabine 1000 mg/m(2), oxaliplatin 100 mg/m(2)) followed by surgery and adjuvant gemcitabine (1000 mg/m(2) for 6 months)
Study: 21831266
Drug: Adjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gemcitabine (1000 mg/m(2) for 6 months) after surgery
Study: 17694216
Drug: Polished and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polished and coated with bonding agent
Study: 11815683
Drug: Psychiatrists with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatrists with a greater percentage of patients on psychotropic medications
Study: 9612620
Drug: Extended neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended neoadjuvant treatment concepts including chemotherapy
Study: 9612620
Drug: Optimal surgical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal surgical treatment
Study: 2491458
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole daily
Study: 2753302
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg/day) for 6 months
Study: 3655305
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg/day)
Study: 31865457
Drug: Sugammadex with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex with hormonal contraception; Counseling provided: 0.7% (1 out of 134 women) had documented counseling on drug-drug interaction.
Study: 31101037
Drug: Weight gain
Normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight gain prevention intervention with tailored behavior change goals, daily weighing on a network-connected electronic scale, and responsive weight and goal coaching delivered remotely by health center registered dietitians.
Study: 19320235
Drug: CLA 2
Normalized name: Jencycla 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA 2 g/day for 4 weeks before and 4 days following intranasal HRV inoculation
Study: 17050768
Drug: Semistructured Interview
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semistructured Interview for Consideration of Ethnic Culture in Therapy Scale (SSICECTS)
Study: 10694141
Drug: CREATINE (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CREATINE (5 g of Cr, four times per day for 6 d)
Study: 10694141
Drug: PLACEBO (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO (same dosage of maltodextrins)
Study: 3204161
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment modalities)
Study: 25716971
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day for 12 weeks
Study: 22700526
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) received a month of weekly 4-hour training for nursing home staff.
Study: 19919298
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of text and graphics presentation format
Study: 10989321
Drug: Doxazosin (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1-4 mg/day)
Study: 9194510
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of hydrochlorothiazide and amiloride
Study: 9194510
Drug: amlodipine and
Normalized name: amlodipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine and combined diuretics
Study: 9194510
Drug: alpha-methyldopa and
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-methyldopa and combination of hydrochlorothiazide and amiloride
Study: 8363072
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine in saline
Study: 8363072
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine in saline
Study: 8363072
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine in 0.25% bupivacaine
Study: 3929694
Drug: PSK, MMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK, MMC and FT combination
Study: 3929694
Drug: PSK administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSK administration
Study: 27129125
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg
Study: 16645424
Drug: K-Mg-citrate (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-Mg-citrate (42 mEq K/d and 21 mEq Mg/d)
Study: 16645424
Drug: K-Mg-citrate
Normalized name: citric acid / potassium citrate Oral Solution [Cytra-K]
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-Mg-citrate
Study: 1840065
Drug: Conventional antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antidepressants
Study: 6974303
Drug: Enpryn, capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enpryn, capsules containing enteric‐coated pellets
Study: 6974303
Drug: Rhusal, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhusal, an enteric‐coated tablet
Study: 6974303
Drug: Enteric‐coated pellet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric‐coated pellet capsules
Study: 30692123
Drug: MAA868, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAA868, single subcutaneous doses
Study: 21545397
Drug: Low-dose valsartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valsartan (10/20 mg)
Study: 21545397
Drug: Medium-dose valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medium-dose valsartan (40/80 mg)
Study: 21545397
Drug: High-dose valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valsartan (80/160 mg)
Study: 11353877
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (lisinopril, 20 mg od)
Study: 17060064
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (lisinopril)
Study: 9398953
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional anaesthesia (IVRA)
Study: 1878535
Drug: Diltiazem 10
Normalized name: diltiazem 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 10 mg
Study: 13678108
Drug: Benzocaine gel
Normalized name: Benzocaine Gel
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzocaine gel
Study: 29283679
Drug: Orthokeratology lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthokeratology lens (treatment)
Study: 29283679
Drug: Both eyes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both eyes (treatment and control)
Study: 25709399
Drug: AZD3199 via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3199 via a Spira nebulizer (Turbuhaler; equivalent delivered doses 5‐3200 μg) or Turbuhaler (single delivered doses of 120‐1920 μg or repeated delivered once‐daily doses 240‐1,680 μg)
Study: 18676275
Drug: Preoperative regional
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative regional intra-arterial chemotherapy (PRAC)
Study: 16169761
Drug: Inhaled Formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Formoterol 9 microg bid
Study: 10714479
Drug: High respirable
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High respirable dose formulation at 30 l min(‐1)
Study: 10714479
Drug: High respirable
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High respirable dose formulation at 60 l min(‐1)
Study: 10714479
Drug: Low respirable
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low respirable dose formulation at 30 l min(‐1)
Study: 10714479
Drug: Low respirable
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low respirable dose formulation at 60 l min(‐1)
Study: 10714479
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of urinary excretion between formulations
Study: 8774398
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose subcutaneous heparin (12,500 units twice per day)
Study: 8774398
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose subcutaneous heparin (5000 units twice per day)
Study: 9174558
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg daily)
Study: 1282178
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 or 20 mg b.i.d.)
Study: 1282178
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 or 80 mg t.i.d.)
Study: 31004969
Drug: Free from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free from Falls Online (FFFO) - eight weekly sessions with instructional and exercise components
Study: 26031820
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment for acute cholecystitis
Study: 24164228
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (InGaAlP laser)
Study: 17024797
Drug: Kanamycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin (100 mg vaginal ovules for 6 days)
Study: 17024797
Drug: Meclocycline (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclocycline (35 mg vaginal ovules for 6 days)
Study: 10685667
Drug: IL-2 and
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 and IFN-alpha combination
Study: 8775698
Drug: Postoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative physical therapy plus continuous passive motion (CPM)